Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan

Neuropharmacology

Volumn 53, Issue 8, 2007, Pages 899-905

  Mogi, Masaki ^a   Tsukuda, Kana ^a   Li, Jian Mei ^a   Iwanami, Jun ^a   Min, Li Juan ^a   Sakata, Akiko ^a   Fujita, Teppei ^a   Iwai, Masaru ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptors; Cognitive impairment; High cholesterol diet; High salt diet

Indexed keywords

CHOLESTEROL; GLUCOSE; OLMESARTAN;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; COGNITION; DIET; DRUG INHIBITION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; METABOLIC SYNDROME X; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TASK PERFORMANCE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; BRAIN; CHOLESTEROL; COGNITION DISORDERS; GENE EXPRESSION REGULATION; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, ANGIOTENSIN; SODIUM CHLORIDE, DIETARY; SUPEROXIDES; TETRAZOLES; UBIQUITIN-CONJUGATING ENZYMES;

EID: 36249007030     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.08.020     Document Type: Article

References (44)

1. Bonarek M., Barberger-Gateau P., Letenneur L., Deschamps V., Iron A., Dubroca B., and Dartigues J.F. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 19 (2000) 141-148
2. Broomfield S., Chow B.L., and Xiao W. MMS2, encoding a ubiquitin-conjugating-enzyme-like protein, is a member of the yeast error-free postreplication repair pathway. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 5678-5683
3. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., and Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
4. Desmond D.W., Tatemichi T.K., Paik M., and Stern Y. Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Arch. Neurol. 50 (1993) 162-166
5. Dobrian A.D., Davies M.J., Schriver S.D., Lauterio T.J., and Prewitt R.L. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 37 (2001) 554-560
6. Dobrian A.D., Schriver S.D., Lynch T., and Prewitt R.L. Effect of salt on hypertension and oxidative stress in a rat model of diet-induced obesity. Am. J. Physiol. Renal Physiol. 285 (2003) F619-F628
7. Elias P.K., Elias M.F., Robbins M.A., and Budge M.M. Blood pressure-related cognitive decline: does age make a difference?. Hypertension 44 (2004) 631-636
8. Engeli S., Schling P., Gorzelniak K., Boschmann M., Janke J., Ailhaud G., Teboul M., Massiera F., and Sharma A.M. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int. J. Biochem. Cell Biol. 35 (2003) 807-825
9. Ghiadoni L., Virdis A., Magagna A., Taddei S., and Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 35 (2000) 501-506
10. Gregg E.W., Yaffe K., Cauley J.A., Rolka D.B., Blackwell T.L., Narayan K.M., and Cummings S.R. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch. Intern. Med. 160 (2000) 174-180
11. Hirano T., Ran J., and Adachi M. Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats. J. Hypertens. 24 (2006) 103-108
12. Hofsaess U., and Kapfhammer J.P. Identification of numerous genes differentially expressed in rat brain during postnatal development by suppression subtractive hybridization and expression analysis of the novel rat gene rMMS2. Brain. Res. Mol. Brain Res. 113 (2003) 13-27
13. Iwai M., Li H.S., Chen R., Shiuchi T., Wu L., Min L.J., Li J.M., Tsuda M., Suzuki J., Tomono Y., Tomochika H., Mogi M., and Horiuchi M. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J. Pharmacol. Exp. Ther. 319 (2006) 1081-1087
14. Iwai M., Liu H.W., Chen R., Ide A., Okamoto S., Hata R., Sakanaka M., Shiuchi T., and Horiuchi M. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110 (2004) 843-848
15. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., Hua T., Laragh J., McInnes G.T., Mitchell L., Plat F., Schork A., Smith B., and Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
16. Keller J.N., Schmitt F.A., Scheff S.W., Ding Q., Chen Q., Butterfield D.A., and Markesbery W.R. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64 (2005) 1152-1156
17. Koike H., Sada T., and Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J. Hypertens. Suppl. 19 (2001) S3-S14
18. Krege J.H., Hodgin J.B., Hagaman J.R., and Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25 (1995) 1111-1115
19. Launer L.J., Masaki K., Petrovitch H., Foley D., and Havlik R.J. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. J. Am. Med. Assoc. 274 (1995) 1846-1851
20. Lethem R., and Orrell M. Antioxidants and dementia. Lancet 349 (1997) 1189-1190
21. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., and Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 21 (2003) 875-886
22. Mariani E., Polidori M.C., Cherubini A., and Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 827 (2005) 65-75
23. Matsushita K., Wu Y., Okamoto Y., Pratt R.E., and Dzau V.J. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 48 (2006) 1095-1102
24. Mogi M., Li J.M., Iwanami J., Min L.J., Tsukuda K., Iwai M., and Horiuchi M. Angiotensin II Type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 48 (2006) 141-148
25. Nussberger J., and Koike H. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil. Clin. Ther. 26 Suppl. A (2004) A12-A20
26. Ogihara T., Asano T., Ando K., Sakoda H., Anai M., Shojima N., Ono H., Onishi Y., Fujishiro M., Abe M., Fukushima Y., Kikuchi M., and Fujita T. High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats. Hypertension 40 (2002) 83-89
27. Ohara Y., Peterson T.E., and Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91 (1993) 2546-2551
28. Ohara Y., Peterson T.E., Sayegh H.S., Subramanian R.R., Wilcox J.N., and Harrison D.G. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 92 (1995) 898-903
29. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., and Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
30. Ruiz-Opazo N., Lopez L.V., and Tonkiss J. Modulation of learning and memory in Dahl rats by dietary salt restriction. Hypertension 43 (2004) 797-802
31. Schiffrin E.L. Progress in secondary prevention of stroke with PROGRESS. The perindopril protection against recurrent stroke study. Curr. Hypertens. Rep. 4 (2002) 39-40
32. Schrader J., Luders S., Kulschewski A., Berger J., Zidek W., Treib J., Einhaupl K., Diener H.C., and Dominiak P. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34 (2003) 1699-1703
33. Shiuchi T., Iwai M., Li H.S., Wu L., Min L.J., Li J.M., Okumura M., Cui T.X., and Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43 (2004) 1003-1010
34. Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson L.A., Nilsson L., Persson G., Oden A., and Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet 347 (1996) 1141-1145
35. Skoog I., Lithell H., Hansson L., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., and Zanchetti A. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am. J. Hypertens. 18 (2005) 1052-1059
36. Szocs K., Lassegue B., Sorescu D., Hilenski L.L., Valppu L., Couse T.L., Wilcox J.N., Quinn M.T., Lambeth J.D., and Griendling K.K. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 21-27
37. Terry Jr. A.V., Hernandez C.M., and Buccafusco J.J. Dahl salt-sensitive and salt-resistant rats: examination of learning and memory performance, blood pressure, and the expression of central nicotinic acetylcholine receptors. Neuroscience 103 (2001) 351-363
38. Tong X.K., Nicolakakis N., Kocharyan A., and Hamel E. Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J. Neurosci. 25 (2005) 11165-11174
39. Wang J.M., Veerasingham S.J., Tan J., and Leenen F.H. Effects of high salt intake on brain AT1 receptor densities in Dahl rats. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H1949-H1955
40. Wattanapitayakul S.K., Weinstein D.M., Holycross B.J., and Bauer J.A. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J. 14 (2000) 271-278
41. Wehr H., Parnowski T., Puzynski S., Bednarska-Makaruk M., Bisko M., Kotapka-Minc S., Rodo M., and Wolkowska M. Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Dement. Geriatr. Cogn. Disord. 11 (2000) 70-73
42. Yaffe K., Blackwell T., Kanaya A.M., Davidowitz N., Barrett-Connor E., and Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63 (2004) 658-663
43. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., Tylavsky F.A., and Newman A.B. The metabolic syndrome, inflammation, and risk of cognitive decline. J. Am. Med. Assoc. 292 (2004) 2237-2242
44. Young S.E., Mainous III A.G., and Carnemolla M. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care 29 (2006) 2688-2693